152 related articles for article (PubMed ID: 31895947)
1. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
Strati P; Schlette EJ; Solis Soto LM; Duenas DE; Sivina M; Kim E; Keating MJ; Wierda WG; Ferrajoli A; Kantarjian H; Estrov Z; Jain N; Thompson PA; Wistuba II; Burger JA
Blood; 2020 Feb; 135(7):510-513. PubMed ID: 31895947
[No Abstract] [Full Text] [Related]
2. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.
Schliffke S; Akyüz N; Ford CT; Mährle T; Thenhausen T; Krohn-Grimberghe A; Knop S; Bokemeyer C; Binder M
Leukemia; 2016 Nov; 30(11):2232-2234. PubMed ID: 27220665
[No Abstract] [Full Text] [Related]
3. Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Albi E; Baldoni S; Aureli P; Dorillo E; Del Papa B; Ascani S; Di Ianni M; Falzetti F; Sportoletti P
Tumori; 2017 Nov; 103(Suppl. 1):e37-e40. PubMed ID: 28708231
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
[TBL] [Abstract][Full Text] [Related]
5. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
6. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Robier C; Beham-Schmid C; Neubauer M
Clin Chem Lab Med; 2018 Apr; 56(5):e112-e114. PubMed ID: 29252190
[No Abstract] [Full Text] [Related]
7. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Mato AR; Roeker LE; Allan JN; Pagel JM; Brander DM; Hill BT; Cheson BD; Furman RR; Lamanna N; Tam CS; Handunnetti S; Jacobs R; Lansigan F; Bhavsar E; Barr PM; Shadman M; Skarbnik AP; Goy A; Beach DF; Svoboda J; Pu JJ; Sehgal AR; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Rhodes J; Ujjani CS; Nabhan C
Am J Hematol; 2018 Nov; 93(11):1394-1401. PubMed ID: 30132965
[TBL] [Abstract][Full Text] [Related]
8. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Shaw Y; Bilotti E; Zhou C; James DF; O'Brien S
Blood; 2015 Apr; 125(16):2497-506. PubMed ID: 25700432
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
10. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
Andrasiak I; Rybka J; Knopinska-Posluszny W; Wrobel T
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):268-273. PubMed ID: 28395851
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
Molica S; Levato L; Mirabelli R; Tedeschi A; Lentini M
Leuk Lymphoma; 2018 Nov; 59(11):2734-2736. PubMed ID: 29465275
[No Abstract] [Full Text] [Related]
13. Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
Shumilov E; Wulf G; Ströbel P; Hasenkamp J; Hellige N; Bleckmann A; Haase D; Braulke F; Jung W; Schanz J; Binder M; Trümper L; Bacher U
Leuk Lymphoma; 2016 Oct; 57(10):2476-80. PubMed ID: 26916814
[No Abstract] [Full Text] [Related]
14. Three years of ibrutinib in CLL.
Forconi F
Blood; 2015 Apr; 125(16):2455-6. PubMed ID: 25883227
[TBL] [Abstract][Full Text] [Related]
15. Counterpoint: Does Chemoimmunotherapy Still Have a Role in CLL? Chemotherapy Can Be Eliminated in the Management of CLL.
Woyach JA
Oncology (Williston Park); 2018 Jun; 32(6):291, 297, 302. PubMed ID: 29940060
[No Abstract] [Full Text] [Related]
16. Life after ibrutinib? A new unmet need in CLL.
Pinilla-Ibarz J; Chavez JC
Blood; 2015 Mar; 125(13):2013-4. PubMed ID: 25814485
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
19. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
20. Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Williams AM; Baran AM; Schaffer M; Bushart J; Rich L; Moore J; Barr PM; Zent CS
Am J Hematol; 2020 Jan; 95(1):E16-E18. PubMed ID: 31621100
[No Abstract] [Full Text] [Related]
[Next] [New Search]
